Clene

Clene Interest Expense

The Interest Expense of Clene (CLNN) as of Oct 16, 2026 is -3.66 M USD. In the previous year, Interest Expense was -1.31 M USD — a change of 178.75% (lower).

Interest Expense

-3.66 MUSD

YoY

178.75%

Last updated:

Interest Expense of Clene is 2024 -3.66 M USD. Interest Expense of Clene was 2023 -1.31 M USD. It decreases by 178.75% lower compared to the previous year.

The Clene Interest Expense history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Interest Expense
Date
Interest Expense
Jan 1, 2018
340,000.00 USD
Jan 1, 2019
860,000.00 USD
Jan 1, 2020
11.74 M USD
Jan 1, 2021
33.08 M USD
Jan 1, 2022
12.54 M USD
Jan 1, 2023
-1.31 M USD
Jan 1, 2024
-3.66 M USD
The Clene Interest Expense history
YEARInterest ExpenseYoY
-3.66 MUSD+178.75%
-1.31 MUSD-110.47%
12.54 MUSD-62.09%
33.08 MUSD+181.77%
11.74 MUSD+1,265.12%
860,000.00USD+152.94%
340,000.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Clene Stock analysis

What does Clene do? Clene Inc is a clinical-stage biopharmaceutical company based in Salt Lake City, Utah, operating within the health care sector and specifically in the biotechnology industry. The company went public via an IPO on August 27, 2018, and currently employs 75 full-time staff. Clene focuses on developing therapeutics for neurodegenerative diseases, with its primary drug candidate being CNM-Au8, an oral suspension of gold nanocrystals. The company's research targets energetic failure, an underlying factor in many neurological conditions, aiming to restore neuronal health and function by enhancing energy production and utilization. CNM-Au8 works through catalytically active nanocrystals that support cellular energy processes, promoting neuroprotection and remyelination by improving resilience to disease-related stressors. The company also has other product candidates, including CNM-ZnAg, a spectrum antiviral and antibacterial agent composed of zinc and silver ions, and CNM-AgZn17, a gel polymer suspension of zinc and silver designed for treating infectious diseases and supporting wound healing. Clene's website is https://clene.com/ and it is listed under the ticker CLNN with ISIN US1856342019. The company remains in the clinical development phase, focusing on advancing its pipeline of treatments for neurological and infectious conditions. Clene is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Clene stock

Interest Expense of Clene is -3.66 M USD in 2024.

Interest Expense of Clene changed from -1.31 M USD to -3.66 M USD, representing a 178.75% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Interest Expense Clene since 2006 – with annual values, charts, and detailed analysis.

Interest expense represents the cost of borrowing. Higher interest expenses can indicate a highly leveraged company.

Interest Expense's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Interest Expense's Clene historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Clene

All Key Metrics — Clene